Case Series

Mild Late-Onset Sensory Neuropathy Associated with Heterozygous Missense GDAP1 Variants

Nivedita U. Jerath

AdventHealth Neuroscience Institute, 1573 West Fairbanks Avenue, Suite 210 Winter Park, Orlando, FL, USA

Correspondence should be addressed to Nivedita U. Jerath; njerath@post.harvard.edu

Received 28 November 2021; Accepted 15 April 2022; Published 24 May 2022

1. Introduction

Charcot–Marie–Tooth disease (CMT) reflects a group of inherited neuropathies affecting 1 in 2,500 individuals [1–3]. CMT type 1A is the most common CMT, accounting for approximately 60% of those with a genetic diagnosis [4]. Classically, CMT is characterized by distal weakness, foot structural deformities, sensory abnormalities, areflexia, and abnormalities in gait [5].

Genetic advances have allowed the classic CMT phenotype to be expanded and evaluated for idiopathic unexplained neuropathies [4]. The rare forms of CMT still need to be understood. This study aims to elucidate our understanding of the clinical features of heterozygous GDAP1 mutations.

GDAP1 mutations can present in both heterozygous and homozygous forms [2, 6]. GDAP1 mutations are responsible for demyelinating intermediate and axonal recessive CMT and CMT 2K, a rare dominant axonal CMT [5, 7–10]. The majority of GDAP1 mutations are biallelic giving rise to autosomal recessive CMT, which can present as either demyelinating [5], axonal [10], or intermediate CMT [11].

Although the homozygous presentation is typically very severe with early childhood onset with motor and sensory involvement and possible vocal fold paresis, the heterozygous form seems much less severe with a late-onset mild sensory presentation [2].

This study further describes the clinical presentation of GDAP1 mutations and adds to the knowledge of heterozygous GDAP1 mutations.

2. Methods

All subjects received care at the AdventHealth Orlando Neuroscience Institute. All had neurological records evaluated. In addition, four out of the five individuals had electrodiagnostic testing performed. Genetic testing for inherited neuropathies was performed through Invitae (San Francisco, CA) [12]. Three pathogenic variants in the GDAP1 gene were identified, and one variant of uncertain significance in the GDAP1 gene was also detected.

3. Results

Case 1. As a child, this subject had no difficulties with running, walking, roller skating, or biking. She was not athletic and was the slowest runner compared to her peers at school but was healthy and active. Her symptoms first
Table 1: Clinical Results of individuals with a heterozygous GDAP1 missense variant.

| Proband | Variants found in heterozygous state | Onset | Clinical symptoms | EMG/NCS | Family history |
|---------|--------------------------------------|-------|------------------|--------|---------------|
| 1       | GDAP1 c.358C>T (p.Arg120Trp), classified as pathogenic | 20s   | Burning feet, intermittent hand numbness; decreased pinprick to midcalf | Absent sural sensory responses bilaterally | Son with high arches at age 10 |
| 2       | GDAP1 c.358C>T (p.Arg120Trp), classified as pathogenic | Early 50s | Not athletic as a child, numb toes, reflexes absent | Right ulnar sensory response mildly reduced amplitude | None |
| 3       | GDAP1 c.811G>A (p.Gly271Arg), classified as pathogenic | Late 60s | Paresthesias and numbness in thumbs and toes, absent achilles reflexes | Normal | Father with neuropathy |
| 4 (proband 3's daughter) | GDAP1 c.811G>A (p.Gly271Arg), classified as pathogenic | 40s   | Fast runner as a child but had cramps; numb toes on left foot | Not performed | |
| 5       | GDAP1 c.1006G>T (p.Ala336Ser); classified as a variant of uncertain significance. | 50s   | Was able to run, walk, and bike as a child up until his 50s when he developed pain in both feet as if “duct tape” around it. | Left superficial peroneal and ulnar sensory and left tibial motor response mildly reduced amplitude | Mother with neuropathic pain. |

started in her 50s when she started to have difficulty with fatigue and numbness in her toes. Occasionally, she will have pain. She has no weakness but does have some difficulty with climbing stairs. Her son was diagnosed with CMT at age 10 due to high arches, which prompted her evaluation for CMT.

Case 2. In her youth, she had no difficulties with running, walking, balance, or athletics. She was a slow runner in general and had weak ankles. Her symptoms started in her 20s when she experienced burning foot pain after standing for prolonged periods. In her 40s, she felt that she started to develop numbness in her feet and mild difficulty with dexterity in her hands. Examination revealed absent Achilles reflexes.

Case 3. As a child, she had no difficulties with running, walking, roller skating, or biking. Although she was not athletic, she was a fast walker. She had some mild tremors throughout her life. She developed burning, tingling, and extreme sensitivity to cold at age 67. She has numbness in her thumbs and paresthesias in her hands and feet. Neurological examination is intact except for absent Achilles reflexes. Both her father and her daughter have CMT 2K.

Case 4. Daughter of the Case 3 proband: as a child, she was athletic and the fastest runner compared to her peers in school. She had cramps and growing pains but no other symptoms; she has normal foot structure. Then, in her 40s, she developed numbness in her left toes and obtained genetic testing due to her mother’s CMT diagnosis.

Case 5. As a child, he was athletic. In his early 50s, he started to develop constant daily pain in both plantar aspects of his feet below the middle toe area. He also has a numb feeling as if someone wrapped duct tape around his foot. Despite pain relieving interventions, including neurontin, pregabalin, marijuana, and acupuncture, he has not had pain relief. He has difficulty walking due to his balance. He had a ruptured Achilles tendon. He walks and rides his bike daily. EMG/NCS showed minor abnormalities to suggest a possible sensorimotor polyneuropathy. Exam is significant for absent ankle jerk reflexes and pinprick sensation decreased up to ankle.

4. Discussion

CMT can have various symptoms and signs, including mild paresthesias, as evidenced in this study. In some cases, genetic testing can reveal underlying causes of idiopathic mild neuropathies.

The findings from the subjects with a heterozygous pathogenic GDAP1 missense variant (Table 1) demonstrate that all presented with a mild sensory neuropathy; all except one subject had a late-onset neuropathy developing after age 40. Electrodiagnostic testing was normal in one of the five individuals, with the other two individuals having minor nerve conduction abnormalities. Neurological exam was normal except for decreased pinprick in proband 1, absent reflexes in proband 2, and absent Achiles reflex in proband 3. There was no family history in proband 2. Proband 1 had a son with high arches in his feet at age 10. Proband 3 has a daughter with numbness in her left toe and a father who had a neuropathy. Proband 5 developed pain in his feet in his 50s.

Previous studies of heterozygous GDAP1 variants suggest a late-onset, slowly progressive, and mild neuropathy [7, 9]. Another earlier study suggested a wide variability in age of onset and severity [13]. Zimon et al. (2011) also reported heterozygous GDAP1 variants with various age onset, but unlike our study, some subjects presented with walking difficulties. However, similar to our study, some subjects were asymptomatic, perhaps due to incomplete penetrance or the nature of the heterozygous form. Electrodiagnostic studies revealed an axonal or an intermediate pattern. A previous study suggested that five variants in the GDAP1 gene (p.Arg120Gly, p.Arg120Trp, p.His123Arg, p.Gln218Glu, and p.Arg226Ser) had a milder and indolent...
clinical course [14]. In general, heterozygous carriers were milder.

The GDAP1 variant is a rare CMT variant in which autosomal recessive and dominant forms can be seen [2]. The GDAP1 gene in a heterozygous form results in a suspected pathology localized to abnormalities in mitochondrial fusion [15].

Classical CMT2 is an axonal CMT with reduced amplitudes [16]. Our subjects had completely normal or borderline electrodiagnostic testing at the time of their evaluations, as seen previously [6]. This can make the diagnosis challenging.

Our subjects were comprised of four women and one man. Men may need to be separately investigated as there might be a gender difference or variability among this population [2].

In summary, CMT should be considered a possible differential in mild late-onset sensory neuropathies with normal to borderline abnormal nerve conduction studies.

Data Availability

The data used to support this article can be made available by the corresponding author on request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The author would like to express her special thanks of gratitude to a fabulous success coach, Dean Graziosi; AdventHealth Orlando Neuroscience Institute; her family/close colleagues; and Seema Sernowitz for her editing services.

References

[1] H. Skre, “Genetic and clinical aspects of Charcot-Marie-Tooth’s disease,” Clinical Genetics, vol. 6, no. 2, pp. 98–118, 1974.

[2] M. Zimon, J. Baets, G. M. Fabrizi, and E. Jaakkola, “Dominant GDAP1 mutations cause predominantly mild CMT phenotypes,” Neurology, vol. 77, no. 6, pp. 540–548, 2011.

[3] A. De Sandre-Giovannoli, M. Chaouch, and J. Boccaccio, “Phenotypic and genetic exploration of severe demyelinating and secondary axonal neuropathies resulting from GDAP1 nonsense and splicing mutations,” Journal of Medical Genetics, vol. 40, no. 7, pp. 87e–87, 2003.

[4] K. M. D. Cornett, M. P. Menezes, P. Bray, and M. Halaki, “Phenotypic variability of childhood charcot-marie-tooth disease,” JAMA Neurology, vol. 73, no. 6, pp. 645–651, 2016.

[5] R. V. Baxter, K. Ben Othmane, J. M. Rochelle, and J. Stajich, “Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21,” Nature Genetics, vol. 30, no. 1, pp. 21-22, 2002.

[6] A. Niemann, K. M. Wagner, M. Ruegg, and U. Suter, “GDAP1 mutations differ in their effects on mitochondrial dynamics and apoptosis depending on the mode of inheritance,” Neurobiology of Disease, vol. 36, no. 3, pp. 509–520, 2009.

[7] R. Claramunt, L. Pedrola, and T. Sevilla, “Genetics of Charcot-Marie-Tooth disease type 4A: mutations, inheritance, phenotypic variability, and founder effect,” Journal of Medical Genetics, vol. 42, no. 4, pp. 358–365, 2005.

[8] J. Senderek, C. Bergmann, and V. T. Ramaekers, “Mutations in the ganglioside-induced differentiation-associated protein-1 (GDAP1) gene in intermediate type autosomal recessive Charcot-Marie-Tooth neuropathy,” Brain, vol. 126, no. 3, pp. 642–649, 2003.

[9] K. W. Chung, S. M. Kim, I. N. Sunwoo, and S. Cho, “A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease,” Journal of Human Genetics, vol. 53, no. 4, pp. 360–364, 2008.

[10] A. Cuesta, L. Pedrola, T. Sevilla, J. M. Garcia-Planells, I. Marin, and J. J. F. Vilchez, “The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease,” Nature Genetics, vol. 30, no. 1, pp. 22–25, 2002.

[11] E. Nelis, S. Erdem, P. Y. K. Van Den Bergh, and M.-C. Belpaire-Dethiou, “Mutations in GDAP1: autosomal recessive CMT with demyelination and axonopathy,” Neurology, vol. 59, no. 12, pp. 1865–1872, 2002.

[12] K. W. D. Ho and N. U. Jerath, “T118M variant of PMP22 gene presents with painful peripheral neuropathy and varying charcot-marie-tooth features: a case series and review of the literature,” Case Reports in Genetics, vol. 2018, Article ID 2618071, 7 pages, 2018.

[13] C. Crimella, A. Tonelli, G. Airoldi, and C. Baschirotto, “The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2K,” Journal of Medical Genetics, vol. 47, no. 10, pp. 712–716, 2010.

[14] I. Pezzini, A. Geroldi, S. Capponi, and R. Gulli, “GDAP1 mutations in Italian axonal Charcot-Marie-Tooth patients: phenotypic features and clinical course,” Neuromuscular Disorders, vol. 26, no. 1, pp. 26–32, 2016.

[15] J. Cassereau, A. Chevrollier, D. Bonneau, C. V. P. Verny, and M. Ferré, “A locus-specific database for mutations in GDAP1 phenotype Genetics,” Journal of Medical Genetics, vol. 42, no. 4, pp. 358–365, 2005.

[16] I. Marín, and J. J. F. Vílchez, “The gene encoding ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A and 2K,” Orphanet Journal of Rare Diseases, vol. 6, no. 1, p. 87, 2011.

[17] I. Banchs, C. Casasnovas, A. Albèrti, L. M. J. De Jorge, and J. A. V. Martinez-Matos, “Diagnosis of charcot-marie-tooth disease,” Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 985415, 10 pages, 2009.